Example: Heart Attack

Search clinical trials for: AstraZeneca

Total 3450 results

NCT04449861

Not yet recruiting

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Conditions: Small Cell Lung Carcinoma Extensive Disease
NCT04449484

Not yet recruiting

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

Conditions: Parkinson's Disease
NCT04445714

Not yet recruiting

To Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus.

Conditions: Type 2 Diabetes Mellitus
NCT04441138

Not yet recruiting

Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC

Conditions: Stage III Non-small-cell Lung Cancer
NCT04438408

Not yet recruiting

National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.

Conditions: Asthma Chronic; Severe Asthma
NCT04435483

Recruiting

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

Conditions: Pharmacokinetics; Bioavailability
NCT04430452

Not yet recruiting

Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition

Conditions: Advanced Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8
NCT04430712

Active, not recruiting

Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume

Conditions: Non-small Cell Lung Cancer
NCT04425200

Not yet recruiting

Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting

Conditions: Prostatic Neoplasms
NCT04421963

Not yet recruiting

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

Conditions: Ovarian Cancer
NCT04416633

Not yet recruiting

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced, NSCLC and Urothelial Cancer

Conditions: Unresectable Non-small Cell Lung Cancer (NSCLC) and Urothelial Cancer
NCT04417062

Not yet recruiting

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Conditions: Osteosarcoma; Osteosarcoma Recurrent
NCT04412070

Not yet recruiting

Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients

Conditions: Bladder Cancer
NCT04410198

Recruiting

Study of Roxadustat Conversion in Subjects Receiving Stable ESA or as Initial Anemia Treatment in Chronic Dialysis Patients

Conditions: Anemia Associated With End Stage Renal Disease (ESRD)
NCT04410796

Recruiting

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Conditions: Metastatic Non-small Cell Lung Cancer
NCT04407091

Not yet recruiting

A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

Conditions: Cardiovascular Disease
NCT04405401

Not yet recruiting

Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

Conditions: Lung Cancer Metastatic
NCT04397003

Not yet recruiting

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer

Conditions: Extensive-stage Small Cell Lung Cancer
NCT04392505

Recruiting

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

Conditions: Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Stage III; NSCLC; NSCLC, Stage III
NCT04391283

Not yet recruiting

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Conditions: Carcinoma, Non-Small-Cell Lung
NCT04385368

Not yet recruiting

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

Conditions: Carcinoma, Non-Small-Cell Lung
NCT04380688

Not yet recruiting

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

Conditions: COVID-19
NCT04381494

Recruiting

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

Conditions: Unresectable Stage III NSCLC
NCT04379596

Recruiting

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)

Conditions: Gastric Cancer
NCT04372927

Not yet recruiting

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
NCT04365218

Not yet recruiting

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease

Conditions: Chronic Kidney Disease
NCT04363697

Not yet recruiting

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

Conditions: Acute Heart Failure; Heart Failure With Reduced Ejection Fraction
NCT04364048

Not yet recruiting

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Conditions: Lung Cancer; Non-small Cell Carcinoma
NCT04361825

Enrolling by invitation

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects

Conditions: Small Cell Lung Cancer
NCT04362410

Active, not recruiting

Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects

Conditions: Healthy Subjects
NCT04353973

Not yet recruiting

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

Conditions: Cancer
NCT04350593

Recruiting

Dapagliflozin in Respiratory Failure in Patients With COVID-19

Conditions: COVID-19
NCT04351256

Recruiting

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy

Conditions: NSCLC, Stage III
NCT04351555

Not yet recruiting

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Conditions: Non-Small Cell Lung Cancer
NCT04346199

Not yet recruiting

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

Conditions: COVID-19
NCT04348045

Not yet recruiting

Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients

Conditions: Metastatic Pancreatic Adenocarcinoma
NCT04336943

Not yet recruiting

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Conditions: Biochemically Recurrent Prostate Carcinoma; Prostate Adenocarcinoma
NCT04334759

Not yet recruiting

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Conditions: Mesothelioma; Pleural Mesothelioma; Malignant Pleural Mesothelioma
NCT04335292

Not yet recruiting

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge

Conditions: Non-Small Cell Lung Cancer
NCT04330040

Recruiting

Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer

Conditions: Ovarian Cancer; Breast Cancer
NCT04327024

Recruiting

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT04307329

Not yet recruiting

Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial

Conditions: Breast Cancer
NCT04307953

Recruiting

Saracatinib Trial TO Prevent FOP

Conditions: Fibrodysplasia Ossificans Progressiva
NCT04305405

Active, not recruiting

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

Conditions: Severe Uncontrolled Asthma
NCT04305496

Recruiting

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2− Breast Cancer

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
NCT04301778

Not yet recruiting

Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Conditions: Unresectable Intrahepatic Cholangiocarcinoma
NCT04298229

Recruiting

Efficacy and Safety of Dapagliflozin in Acute Heart Failure

Conditions: Heart Failure; Diabetes Mellitus, Type 2
NCT04294498

Not yet recruiting

Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection

Conditions: Advanced Hepatocellular Carcinoma
NCT04293172

Not yet recruiting

Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.

Conditions: Sickle Cell Disease
NCT04293419

Recruiting

Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

Conditions: Rectal Cancer